Discover, Advance & Action Emerging RNA Therapeutics to
Optimize Treatment for the CNS

With recent approvals of oligonucleotides for Duchenne Muscular Dystrophy, the discovery of innovative new drug delivery platforms, and investment pouring into neuromuscular and neurodegenerative diseases with RNA therapeutics growing; the door to therapeutic opportunity of novel ASO, RNAi, and other RNA therapeutics for CNS disorders is wide open.

The 1st Oligonucleotides for CNS Summit is a unique opportunity for biopharma to discuss the chemistry of oligonucleotides in the context of CNS biology by gathering pioneering pharma, innovative biotech, and KOLs of academia across disciplines to unite and harness the potential of oligonucleotide therapeutics for neurodegenerative and neuromuscular disorders.

From overcoming extra-hepatic delivery challenges to translating preclinical successes into appropriate clinical paradigms, join industry experts from Alnylam Pharmaceuticals, AstraZeneca, Biogen, and more as they guide you through the seminal research that’s propelling oligonucleotide therapeutics forward in 2021 and beyond.